Patent · US Active

Treatment for cerebral palsy impaired speech in children

US8883815B2 · kind B2 · utility

12Cited by

3References

37Claims

0Family size

Assignee

GILROSE PHARMACEUTICALS, LLC · US

Inventors

Bruce Roseman · White Plains, US
Gilla Kaplan · New York, US

Key dates

Filing date	Oct 22, 2013
Grant date	Nov 11, 2014
Priority date	—
Expiry date	Oct 22, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/5375
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Cerebral palsy impaired speech in children and adolescents are effectively treated by administration of a psychostimulant. Low doses of the psychostimulant significantly increases the percentage of correctly pronounced intelligible syllables or words and the ability to more intelligibly communicate. The improvement in speech persists after cessation of or prior to continued psychostimulant treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.